wonderland

PERAK, July 28 (Bernama) — Tin miner and metal producer, Malaysia Smelting Corporation Berhad (“MSC” or “the Group”) has contributed to the development of a new mosque, Masjid Klian Intan located in the district of Pengkalan Hulu, with a donation cheque worth RM20,000.

The cheque was presented by Encik Madzlan Zam, Senior General Manager of MSC’s tin mining operations, to the Jawatankuasa Kariah Masjid Klian Intan during the Mosque Handover Ceremony held on 24th July 2020. The ceremony was attended by a representative of the royal palace of the Perak Sultanate, Orang Besar Jajahan Hulu Perak, Dato’ Meor Roslan bin Dato’ Seri Hj. Meor Ahmad Rashidi.

Encik Madzlan Zam, Senior General Manager of MSC’s tin mining operations said, “As a responsible corporate citizen, MSC has always taken into consideration the interest of the community of where we operate. The people of Klian Intan have played a big role in the growth of MSC Group over the years. This is one of the ways for us to contribute and further enrich the livelihoods of the surrounding community.”

“Giving back to the larger society is an integral element of MSC’s identity. This initiative is part of MSC’s Corporate Social Responsibility (“CSR”) programme whereby we connect and foster stronger relationship with the community, while supporting the state government. We hope that our contribution will serve the people of Klian Intan well.”

MSC operates the country’s largest hard-rock open-pit tin mine in Klian Intan, Perak known as Rahman Hydraulic Tin Mine. In 2019, 83% of MSC’s tin mining operations’ workforce comprise of locals from Pengkalan Hulu and the nearby communities.

Photo
A photo from the ceremony can be downloaded from here: https://we.tl/t-6AEFKqeGuh, with the caption:
Senior General Manager of MSC’s tin mining operations, Encik Madzlan Zam (left) presenting a donation cheque to Dato’ Meor Roslan (right), Orang Besar Jajahan Hulu Perak, a representative of the royal palace of Perak.

ABOUT MALAYSIA SMELTING CORPORATION BERHAD
The MSC Group is currently one of the world’s leading integrated producers of tin metal and tin based products and a global leader in custom tin smelting since 1887. MSC which is a subsidiary of The Straits Trading Company Limited of Singapore is listed both on the Main Market of Bursa Malaysia and the Main Board of Singapore Exchange.

Released on behalf of Malaysia Smelting Corporation Berhad by Capital Front Investor Relations.

SOURCE: Capital Front PLT

FOR MORE INFORMATION, PLEASE CONTACT:
Name: Keow Mei-Lynn
Tel: 012-250 5575
Email: meilynn@capitalfront.biz

—BERNAMA

KUALA LUMPUR, July 21 — ‘A Bite of Dongguan’ documentary was recently broadcast on the Internet in China, presenting more than 130 kinds of Dongguan’s local ingredients and dishes.

According to a statement, the documentary was planned by the Information Office of Dongguan Municipality, and produced by China’s top food and cultural documentary team. 

Demonstrating the human interest of the ‘world factory’, it has received nearly 100 million reviews and obtained widespread attention.

Through a series of lively characters and stories, it reveals the diverse food culture of the manufacturing city, displays the well-kept tradition during the city’s fast development and shows local people’s attitude for life.

‘A Bite of Dongguan’ is inspired by the city itself, and the people filmed in the documentary. People living in the city, whether local or otherwise, have given Dongguan cuisine new features as being traditional, easy-going, embracing and pragmatic. 

The documentary allows locals to find their identity. It also functions as a communication platform for Dongguan to improve city image through local cuisine

Now, ‘A Bite of Dongguan’ has begun to be released overseas. It is hoped more people in the world will fall in love with Chinese cuisine and understand Dongguan, via its food.

— BERNAMA

KUALA LUMPUR, July 21 — The theme song of the 6th Asian Beach Games, as well as the slogan, nicknames, emblem and theme song of volunteers were released in Sanya, China recently.

Theme song lyricist, Zheng Hai said the song quoted the English slogan of the Games, ‘See ya in Sanya’, highlighting international elements and extending sincere invitations to athletes and tourists worldwide.

“The melody of the song is very consistent with Hainan’s geographical features, which reminds people of the spectacular ebb and flow of the sea,” said theme song singer, Chen Chusheng in a statement.

On the other hand, the volunteers’ slogan is ‘Meet in ABG, Bring Love to the World’, which implies that the ABG brings volunteers from all walks of life together in Sanya.

The nicknames of volunteers are ‘Deer Brother’ and ‘Deer Sister’, which not only include the Hainan Eld’s deer, which is the prototype of the ABG mascot, ‘Yaya’, but also incorporate the distinctive local dialect ‘Age’ (brother) and ‘Amei’ (sister).

The volunteers’ emblem, based on ABG’s emblem, is designed with an additional ‘loving heart’, which echoes the volunteers’ slogan and conveys the volunteers’ perception of ‘loving the ABG’.

The theme song of volunteers, entitled ‘Meet with You and Warm You Up’, is created in the style of a lyric pop song, promoting ‘Dedication, Friendship, Mutual Assistance and Progress’, vividly showing the demeanour of ABG’s volunteers.

— BERNAMA

KUALA LUMPUR, July 17 — Mary Kay Inc has expanded its partnership with The Nature Conservancy to impact waterways and native species worldwide.

According to a statement, last year, Mary Kay had partnered with the conservation organisation to protect Texas fisheries and the Gulf of Mexico.

Beyond the Texas fisheries programme, Mary Kay will also support The Nature Conservancy’s programmes in Australia, New Zealand, Mexico, China, General Ocean, Solomon Islands, Colombia, Canada and Europe.

In Northern Australia, Mary Kay will partner with indigenous communities to increase women’s role in conservation, including establishing a women’s camp at Fish River Station, a 445,000-acre property in the Northern Territory.

While in New Zealand, Mary Kay and The Nature Conservancy will engage with indigenous people in sustainable aquaculture, including supporting the implementation of restorative activities in Auckland’s Hauraki Gulf to restore wild shellfish populations.

In the United Kingdom and Germany, the partnership will work to protect biodiversity and marine resources as they introduce the native European oyster. In Spain, they will work to create a water fund.

Mary Kay also sponsored EarthxOcean conference, bringing experts, researchers and conservations in a livestream to discuss topics such as the High Seas Initiative, coral reef restoration, ocean plastic solutions and sustainable fisheries.

— BERNAMA

GUANGZHOU, China, July 16 (Bernama-BUSINESS WIRE) — LintonPharm Co. Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T-cell engaging bispecific antibodies for cancer immunotherapy, today announced the China National Medical Products Administration (NMPA) authorized the company to proceed with a Phase III trial (clinicaltrials.gov: NCT04222114) for catumaxomab in patients with peritoneal carcinomatosis, a form of advanced gastric cancer that has spread to the tissue that lines the abdominal cavity.

The two-stage, multi-center, open-label, randomized, controlled registrational clinical trial will evaluate the safety and efficacy of an intraperitoneal infusion of the bi-specific antibody catumaxomab into the abdominal cavity in patients with peritoneal carcinomatosis. LintonPharm also recently received Clinical Trial Application (CTA) authorization for the same indication from the Taiwan Ministry of Health and Welfare (MOHW) and the Korea Ministry of Food and Drug Safety (MFDS).

“We are excited to re-initiate clinical development of catumaxomab which we believe may have benefit in a broad range of cancers,” said Robert Li, co-founder and CEO of LintonPharm. “Our initial development strategy is based on a robust foundation of clinical data that support the therapeutic potential of catumaxomab in advanced gastric cancer.”

Catumaxomab was the first T-cell engaging bispecific antibody approved by the European Medicines Agency (EMA) in 2009 for the treatment of malignant ascites, a fluid buildup in the peritoneal cavity that indicates the presence of malignant cells. It was later voluntarily withdrawn from the market for commercial reasons.

“Gastric cancer is the sixth most common cancer globally. Approximately 70 percent of patients are located in China and the majority of these patients are diagnosed with late stage disease. Given this high unmet need, we are hopeful that catumaxomab will offer a new treatment option to gastric patients,” said Dr. Horst Lindhofer, co-founder and Chief Scientific Officer of LintonPharm.

About Advanced Gastric Cancer with Peritoneal Carcinomatosis

Gastric cancer is the sixth most common cancer globally with an estimated incidence of 1,033,701 cases and 782,685 deaths in 2018.¹About 70 percent of gastric cancer patients are located in China, with 679,100 new cases and 489,000 deaths² in 2015. More than 70 percent of Chinese patients are diagnosed with late stage (stage III or IV) gastric cancer. Peritoneal carcinomatosis (PC) is one of the primary causes of death in late stage gastric cancer. Approximately 20 percent of patients are diagnosed with PC before or during surgery, and more than 50 percent of patients are diagnosed with PC after cancer reduction surgery. The prognosis for gastric cancer with PC is extremely poor, with an expected survival of less than one year³. Current therapies for gastric cancer include trastuzumab for Her2 positive patients and systemic chemotherapies (1^st line and 2^nd line). There are limited options for patients who fail frontline therapies, especially for those who developed PC.

About Catumaxomab

Catumaxomab is a trifunctional bispecific antibody which originated from Lindis Biotech’s Triomab platform. The antibody binds to a transmembrane glycoprotein on the tumor cell–the epithelial cell adhesion molecule (EpCAM)–and CD3 on the T-cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab kills tumor cells by engaging T-cell and accessory cell mediated cytotoxicity and has potential to induce long-term vaccinal effects against tumor cells due to the unique FcγR binding and activation profile.

Catumaxomab was first approved by the EMA in 2009 for the treatment of malignant ascites (MA). MA is manifested as the abnormal accumulation of fluid in the peritoneal cavity, which develops from the proliferation of peritoneal carcinomatosis tumor cells in the cavity. There are various cancers that generate MA, for example ovarian, gastric, pancreatic and colorectal cancers. Patients with MA are usually diagnosed in the advanced stages of disease and their quality of life is greatly impaired. Currently, these patients face an extremely poor prognosis with a median overall survival of one to six months.

About LintonPharm

LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. The company’s lead development program is with catumaxomab, a clinically validated bispecific antibody which was the first approved T-cell engager, and its associated Triomab technology platform. LintonPharm, in collaboration with Lindis Biotech, is also developing a next generation bispecific antibody platform known as Fleximab which aims to provide better CMC developability and less immunogenicity. The LintonPharm pipeline includes several treatments in development for blood cancer and solid tumors that use the Triomab and Fleximab platforms. For more information, please visit www.lintonpharm.com.

References

1. Freddie Bray et. al., Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2018; 68: 394-424.
2. Wanqing Chen et. al., Cancer Statistics in China, 2015. CA Cancer J. Clin 2016; 66: 115-132
3. China anti-cancer Association, Gastric Cancer, China Experts Consensus on Gastric Cancer with Peritoneal Carcinomatosis Prevention and Treatment;Chin J Gastrointest Surg, May 2017, Vol. 20, No. 5.
    

​View source version on businesswire.com: 
https://www.businesswire.com/news/home/20200715005898/en/

Contact

Media:
Tara Cooper
The Grace Communication Group
tara@gracegroup.us
650-303-7306

Source : LintonPharm Co. Ltd.